Cargando…

Pharming Promises and risks ofbBiopharmaceuticals derived from genetically modified plants and animals /

Recent scientific advances have made it possible to produce biopharmaceuticals in genetically modified plants and animals, such as maize, tobacco, goats, and chickens. This new branch of biotechnology is termed pharming, composed of the terms pharmaceuticals and farming. Pharming constitutes an over...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autores principales: Rehbinder, Eckard (Autor), Engelhard, Margret (Autor), Hagen, Kristin (Autor), Jørgensen, R. B. (Autor), Pardo Avellaneda, Rafael (Autor), Schnieke, Angelika (Autor), Thiele, Felix (Autor)
Autor Corporativo: SpringerLink (Online service)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Berlin, Heidelberg : Springer Berlin Heidelberg : Imprint: Springer, 2009.
Edición:1st ed. 2009.
Colección:Ethics of Science and Technology Assessment, 35
Temas:
Acceso en línea:Texto Completo

MARC

LEADER 00000nam a22000005i 4500
001 978-3-540-85793-8
003 DE-He213
005 20220114155142.0
007 cr nn 008mamaa
008 100301s2009 gw | s |||| 0|eng d
020 |a 9783540857938  |9 978-3-540-85793-8 
024 7 |a 10.1007/978-3-540-85793-8  |2 doi 
050 4 |a RM300-666 
072 7 |a MMG  |2 bicssc 
072 7 |a MED071000  |2 bisacsh 
072 7 |a MKG  |2 thema 
082 0 4 |a 615  |2 23 
100 1 |a Rehbinder, Eckard.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a Pharming  |h [electronic resource] :  |b Promises and risks ofbBiopharmaceuticals derived from genetically modified plants and animals /  |c by Eckard Rehbinder, Margret Engelhard, Kristin Hagen, R. B. Jørgensen, Rafael Pardo Avellaneda, Angelika Schnieke, Felix Thiele. 
250 |a 1st ed. 2009. 
264 1 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg :  |b Imprint: Springer,  |c 2009. 
300 |a XX, 334 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Ethics of Science and Technology Assessment,  |x 1860-4811 ;  |v 35 
505 0 |a The technology of pharming -- Risk assessment of plant pharming and animal pharming -- The welfare of pharming animals -- Public views and attitudes to pharming -- The ethical evaluation of pharming -- The role of patents in the development of pharming -- Legal problems of pharming -- Conclusions and recommendations. 
520 |a Recent scientific advances have made it possible to produce biopharmaceuticals in genetically modified plants and animals, such as maize, tobacco, goats, and chickens. This new branch of biotechnology is termed pharming, composed of the terms pharmaceuticals and farming. Pharming constitutes an overlap of red and green biotechnology. It offers the prospect of a quicker, cheaper, and more flexible production of biopharmaceuticals compared with current production processes. This is a promising perspective in light of the rapidly growing market of biopharmaceuticals, although the economic competitiveness of pharming remains to be proven. Besides possible benefits for producers, patients and health care systems, pharming also raises a number of complex ecological, social, moral and legal questions that have as yet not been thoroughly discussed. The present book contains the findings of an interdisciplinary research project that has addressed a large range of questions associated with pharming: An analysis of the state-of-the-art of plant pharming and animal pharming technologies is followed by an assessment of environmental risks related to pharming and welfare risks for pharming animals. Public views and attitudes to pharming are investigated on the basis of a comprehensive survey in 15 countries. Moreover, ethical and legal questions, posed by present and foreseeable future practices of pharming, are analysed. The concluding chapter presents the authors' main findings and recommendations, addressed to science, industry, politics and general public interested in the chances and risks of this upcoming field of biotechnology. 
650 0 |a Pharmacology. 
650 0 |a Biotechnology. 
650 0 |a Ethics. 
650 0 |a Biomedical engineering. 
650 1 4 |a Pharmacology. 
650 2 4 |a Chemical Bioengineering. 
650 2 4 |a Moral Philosophy and Applied Ethics. 
650 2 4 |a Biomedical Engineering and Bioengineering. 
700 1 |a Engelhard, Margret.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
700 1 |a Hagen, Kristin.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
700 1 |a Jørgensen, R. B.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
700 1 |a Pardo Avellaneda, Rafael.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
700 1 |a Schnieke, Angelika.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
700 1 |a Thiele, Felix.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9783540858041 
776 0 8 |i Printed edition:  |z 9783642099359 
776 0 8 |i Printed edition:  |z 9783540857921 
830 0 |a Ethics of Science and Technology Assessment,  |x 1860-4811 ;  |v 35 
856 4 0 |u https://doi.uam.elogim.com/10.1007/978-3-540-85793-8  |z Texto Completo 
912 |a ZDB-2-SBL 
912 |a ZDB-2-SXB 
950 |a Biomedical and Life Sciences (SpringerNature-11642) 
950 |a Biomedical and Life Sciences (R0) (SpringerNature-43708)